Therapeutic Asset Ratings
124 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Capivasertib
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P2
B
(58)
Crizotinib
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P2
B
(58)
FLUOROURACILUM
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(58)
Gdc-0449
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P2
B
(58)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P2
B
(58)
Tak-228
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P2
B
(58)
Talzenna
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(58)
Trastuzumab Deruxtecan
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(58)
VEMURAFENIB
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P2
B
(58)
MEGESTROL ACETATE IMPURITY B
Advanced Malignant Solid Neoplasm
Alliance for Clinical Trials in Oncology
P3
B
(57)
azd6244
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Binimetinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Copanlisib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Dasatinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Fexagratinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Hydroxychloroquine
Advanced Malignant Solid Neoplasm
Northwestern University
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Ipilimumab
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P1/2
CCC
(55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Abemaciclib
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P2
CCC
(53)
ag-120
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Anamorelin
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P2
CCC
(53)
Bendamustine
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Dabrafenib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Showing 26 to 50 of 124 assets
Previous
Page 2 of 5
Next